FDA warns CanaRx to stop distributing ‘unapproved, misbranded’ drugs

The FDA recently posted a warning letter to CanaRx requesting it immediately stop dispensing “unapproved new drugs” and “misbranded, potentially dangerous drugs” to U.S. consumers.
The letter references the hepatitis-indicated drug Baraclude; the organ rejection-indicated drugs CellCept and Zortess; the asthma and COPD-indicated drug Foradil; the cancer-indicated drugs Gilotrif, Gleevec, Inlyta, and Stivarga; the HIV-indicated drugs Invirase, Norvir, Reyataz, and Truvada; the epilepsy and nerve pain-indicated drug Tegretol; the pulmonary arterial hypertension-indicated

Source link

Back to top button